BAYER REMAINS NUMBER ONE ASPIRIN BRAND WITH 22% SHARE
This article was originally published in The Tan Sheet
Executive Summary
BAYER REMAINS NUMBER ONE ASPIRIN BRAND WITH 22% SHARE in the U.S., SmithKline Beecham noted in acquisition background materials. Sales for the Bayer brand in the U.S., including the two-year-old Bayer Select line of analgesics, were $132.1 mil. in the 12 months through March, based on Towne-Oller data. In the U.S., SB's analgesic presence is limited to Ecotrin enteric-coated aspirin.